BlueStone Venture Partners
VC Fund
Tucson, United States
BlueStone Venture Partners is a life science venture capital fund investing in entrepreneurial companies.The fund provides strategic capital and support to early-stage life science companies, primarily in Series A and Series B equity rounds. It focuses on medical devices, health IT, advanced materials, and molecular diagnostics.Mara Aspinalland Thomas Nickoloff launched the venture capital fund in Tucson, Arizona in 2018.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
- Fund size:
- $8.9M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BlueStone Venture Partners invests in
Stages BlueStone Venture Partners invests in
Countries BlueStone Venture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mara Aspinall
|
|||
Mara Aspinall
|
|||
Investment Focus
Industry
- Medical 4 (36%)
- Health Care 4 (36%)
- Biotechnology 4 (36%)
- Medical Device 4 (36%)
- Eyewear 1 (9%)
Stage
- Series B 6 (55%)
- Series A 3 (27%)
- Series C 2 (18%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mara Aspinall
Co-founder and managing director
|
Co-founder and managing director | Total investments: 0 | Find email | |
|
Mara Aspinall
Co-founder and managing director
|
Co-founder and managing director | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GT Medical Technologies
|
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $45M / Series C / Mar 23, 2023 | |
GT Medical Technologies
|
GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $45M / Series C / Mar 23, 2023 | |
Elucid
|
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from asingle CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services. | $27M / Series B / Jun 22, 2022 | |
Akadeum Life Sciences
|
Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other relatedareas.Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States. | $17.5M / Series B / Oct 12, 2021 | |
|
Elucid
|
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from asingle CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services. | $10M / Series A / May 10, 2021 | |
|
GT Medical Technologies
|
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $16M / Series B / Nov 23, 2020 | |
|
GT Medical Technologies
|
GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $16M / Series B / Nov 23, 2020 | |
Pyx Health
|
Pyx Health is a mobile solution that reduces loneliness and social isolation. It connects members outside of the traditional care setting. By providing critical and timely interventions and addressing social determinants of health, it takes care of the members when they are most vulnerable, especially after a transition of care.Pyx Health offersPyxir, an endearing chatbot personality that walks alongside your members in their health care journey. Affectionately referred to as ‘he’ by our members, Pyxir promotes healthy interaction within the app by building trusted companionship with its members 24/7.It was founded in 2017 and is headquartered in Tucson, Arizona. | $3.5M / Series B / May 18, 2020 | |
Paradigm Diagnostics
|
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of thepatient’s tumor; thus, personalizing each patient’s course of treatment. | $15M / Series B / May 21, 2019 | |
|
GT Medical Technologies
|
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $10M / Series A / Jan 31, 2019 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does BlueStone Venture Partners invest in?
BlueStone Venture Partners invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BlueStone Venture Partners?
Public channels for BlueStone Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BlueStone Venture Partners?
The team at BlueStone Venture Partners includes Mara Aspinall (Co-founder and managing director) and Mara Aspinall (Co-founder and managing director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
